Results 101 to 110 of about 234,795 (273)

Potential of Ginkgo biloba Extract to Intervene in Chronic Inflammation‐Related Diseases

Phytotherapy Research, EarlyView.
Chronic inflammation is a pathological mechanism underpinning many diseases. Ginkgo biloba extract (GBE) is well known for its anti‐inflammatory property. GBE and its active constituents have been shown to attenuate pro‐inflammatory cytokine production, suppress nuclear factor kappa B activation, restore redox homeostasis, and modulate disease‐relevant
Yipeng Lin, Inho Cho, Xue Zhu, Ke Wang, Ling Zhu, Wenchang Wong, Michael Murray, Fanfan Zhou   +7 more
wiley   +1 more source

The Role of TNF - α, IFN - γ, and IL-6 in Guiding Treatment and Predicting Prognosis in the Treatment of Severe Plaque Psoriasis with Adalimumab

Indian Journal of Dermatology
The clinical efficacy of adalimumab in treating severe plaque psoriasis is significant, but many questions and uncertainties remain. To evaluate the efficacy of adalimumab in treating patients with severe plaque psoriasis and to explore potential ...
Jian-Qing Zhang, Ying Zhang, Hong Chen, Hong-Gang Sun   +3 more
doaj   +1 more source

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5‐Year Analysis of the Phase 3 POETYK PSO‐1, PSO‐4, and Long‐Term Extension Trials

The Journal of Dermatology, EarlyView.
ABSTRACT Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6 mg once daily was efficacious and well tolerated through 3 years in the pooled population of ...
Yukari Okubo, Akimichi Morita, Yayoi Tada, Shinichi Imafuku, April W. Armstrong, Andrew Blauvelt, John Vaile, Zoran Popmihajlov, Janice Li, Rajesh Sawant, Katsuyoshi Habiro, Katsuki Tsuritani, Mamitaro Ohtsuki   +12 more
wiley   +1 more source

Antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy

mBio
A crucial step in lowering the risk of invasive pneumococcal illness in high-risk populations, such as individuals with plaque psoriasis, is pneumococcal vaccination.
Lorena Helmer, Lukas van de Sand, Thea Wojtakowski, Mona Otte, Oliver Witzke, Wiebke Sondermann, Adalbert Krawczyk, Monika Lindemann   +7 more
doaj   +1 more source

Serum Levels of LL-37 and Inflammatory Cytokines in Plaque and Guttate Psoriasis

Mediators of Inflammation, 2014
Psoriasis is a chronic inflammatory skin disease. It is assumed that the plaque phenotype of psoriasis is associated with T helper (Th) 1 immune response activation, while the guttate phenotype is associated with the Th17 immune response.
Young Ji Hwang, Ho Jung Jung, Min Jung Kim, Nam Kyung Roh, Jae Wook Jung, Yang Won Lee, Yong Beom Choe, Kyu Joong Ahn   +7 more
doaj   +1 more source

CLINICAL PRESENTATION OF PSORIASIS

Reumatismo, 2011
SUMMARY Psoriasis is a chronic, inflammatory disease affecting 1-3% of the world’s population. Joints can be affected in up to 30% of patients. About one third of patients have either severe or moderate (involving more than 10% of body surface area ...
F. Ayala
doaj   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case–control study and serological comparison

Frontiers in Medicine
BackgroundThe relationship between plaque psoriasis and both MASLD and lean MASLD has not been sufficiently explored in the current literature.MethodThis retrospective and observational study was carried out from January 2021 to January 2023 at The First
Zheng Lin, Yue-yi Shi, Lu-yan Yu, Chen-xi Ma, Si-yi Pan, Yuan Dou, Qiu-jun Zhou, Yi Cao   +7 more
doaj   +1 more source

Tacrolimus ointment for the treatment of severe facial plaque psoriasis.

, 2005
Contains fulltext : 47356.pdf (Publisher’s version ) (Closed access)Recently, tacrolimus ointment has proved to be effective and well tolerated in patients with facial psoriasis.
PGM Van Der Valk, Valk, P.G.M. van der, Erceg, A., K Maimets, EBM Kroft, A Erceg, PCM Van De Kerkhof, Maimets, K., W Vissers, Kroft, E.B.M., Kerkhof, P.C.M. van de, Vissers, W.H.P.M.   +11 more
core   +1 more source

Real‐World Effectiveness, Treatment Course, and Safety of Tapinarof Cream 1% for Atopic Dermatitis and Plaque Psoriasis in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Background Tapinarof cream 1%, a non‐steroidal topical aryl hydrocarbon receptor‐modulating agent, is approved in Japan for atopic dermatitis (AD) and plaque psoriasis. Real‐world data on longitudinal outcomes, treatment continuation, interruption and restart, and adverse‐event timing are limited. Methods This single‐center retrospective study
Kanade Iino, Saori Takamura, Tomoo Fukuda   +2 more
wiley   +1 more source